These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7163785)

  • 1. Continence training of children with neurogenic bladder and detrusor hyperactivity: effect of atropine.
    Naglo AS
    Scand J Urol Nephrol; 1982; 16(3):211-5. PubMed ID: 7163785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of atropine and isoprenaline on detrusor hyperactivity in children with neurogenic bladder.
    Naglo AS; Nergårdh A; Boréus LO
    Scand J Urol Nephrol; 1981; 15(2):97-102. PubMed ID: 7330612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of adrenergic agonists and antagonists on urethral pressure, bladder pressure and detrusor hyperactivity in children with myelodysplasia.
    Amark P; Nergårdh A
    Acta Paediatr Scand; 1991; 80(8-9):824-32. PubMed ID: 1957602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.
    Amark P; Bussman G; Eksborg S
    Eur Urol; 1998 Aug; 34(2):148-53. PubMed ID: 9693251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations on the internal sphincter mechanism during the filling phase in children with hyperactive neurogenic bladder.
    Nergårdh A; Naglo AS
    Scand J Urol Nephrol; 1982; 16(3):205-9. PubMed ID: 7163784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urodynamic effects of intravesical instillation of atropine and phentolamine in patients with detrusor hyperactivity.
    Ekström B; Andersson KE; Mattiasson A
    J Urol; 1993 Jan; 149(1):155-8. PubMed ID: 8417203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Validation of the treatment of the neurogenic bladder in children with myelodysplasia using pikamilon].
    Vishnevskiĭ EL; Guseva NB
    Urol Nefrol (Mosk); 1998; (2):27-30. PubMed ID: 9577700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of phenylpropanolamine on incontinence in children with neurogenic bladders. A double-blind crossover study.
    Amark P; Beck O
    Acta Paediatr; 1992 Apr; 81(4):345-50. PubMed ID: 1606397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary continence outcome after augmentation ileocystoplasty as a single surgical procedure in patients with myelodysplasia.
    Medel R; Ruarte AC; Herrera M; Castera R; Podesta ML
    J Urol; 2002 Oct; 168(4 Pt 2):1849-52. PubMed ID: 12352374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
    Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
    J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical instillation of atropine in treatment of detrusor overactivity in children].
    Kroll P; Jankowski A; Martyński M
    Wiad Lek; 1998; 51 Suppl 3():87-91. PubMed ID: 9814113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study.
    Lazzeri M; Calò G; Spinelli M; Guerrini R; Salvadori S; Beneforti P; Sandri S; Regoli D; Turini D
    Urology; 2003 May; 61(5):946-50. PubMed ID: 12736013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of intravesical oxybutynin chloride in children with neurogenic bladder.
    Greenfield SP; Fera M
    J Urol; 1991 Aug; 146(2 ( Pt 2)):532-4. PubMed ID: 1861294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for neurogenic detrusor overactivity.
    Chancellor MB; Anderson RU; Boone TB
    Am J Phys Med Rehabil; 2006 Jun; 85(6):536-45. PubMed ID: 16715024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of detrusor hyperactivity in children with neurogenic bladder.
    Naglo AS; Nergårdh A
    Scand J Urol Nephrol; 1981; 15(2):91-6. PubMed ID: 7330611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries.
    Kuo HC; Liu SH
    Neurourol Urodyn; 2011 Nov; 30(8):1541-5. PubMed ID: 21717505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.